Literature DB >> 22398968

Bridging strategies for drug combinations in pediatric indications.

M Cella1, M Danhof, O Della Pasqua.   

Abstract

Concurrent prescription of different drugs is common and is often necessary in many pediatric indications. A randomized concentration-controlled trial (RCCT) is proposed for pediatric studies in which drug combinations are used. The aim of our investigation was to show the relevance of flexible designs for accurate dose selection in such cases. We used the combination of atovaquone (ATV) and proguanil (PGN) as a paradigm to illustrate our approach. Pharmacokinetic models were developed for ATV and PGN using data pertaining to adults. The median area under the curve (AUC) in adults was considered the target exposure for bridging purposes. A pediatric population was simulated according to scenarios in which clearance varied from 20 to 100% of the reference adult values or allometrically correlated with body weight (BW). Doses were subsequently adapted according to the individual AUC estimates. Our results show that adaptive protocols are critical for accurate dose selection when evaluating drug combinations in children, ensuring that target exposure is achieved with respect to both active moieties in each individual patient.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22398968     DOI: 10.1038/clpt.2011.298

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  2 in total

1.  Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part I: Frequentist Approaches.

Authors:  G Smania; P Baiardi; A Ceci; P Magni; M Cella
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-06-01

Review 2.  How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians.

Authors:  Eric Vermeulen; John N van den Anker; Oscar Della Pasqua; Kalle Hoppu; Johanna H van der Lee
Journal:  J Pharm Pharmacol       Date:  2016-09-27       Impact factor: 3.765

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.